-
Something wrong with this record ?
Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient
E. Dvořáčková, A. Zajacová, J. Havlín, E. Klapková, R. Lischke, O. Slanař, M. Šíma
Language English Country Czech Republic
Document type Case Reports, Journal Article
Grant support
00064203
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
from 2012
Medline Complete (EBSCOhost)
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- MeSH
- Aspergillosis * drug therapy MeSH
- Humans MeSH
- Drug Monitoring MeSH
- Mucormycosis * diagnosis drug therapy MeSH
- Lung MeSH
- Transplant Recipients MeSH
- Triazoles therapeutic use pharmacokinetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
Mucormycosis is a rare invasive fungal disease diagnosed in immunocompromised patients, including those with diabetes or iron overload, and in patients treated for hematological malignancies or after transplantation. Isavuconazole is a triazole antifungal effective against Mucorales with good tolerability, but with potential for relatively high interindividual variability in pharmacokinetics. This report demonstrates the case of a lung transplant recipient treated with isavuconasole that exhibits a very long elimination half-life of 159 hours, and discusses the practical implications of this finding for dosage adjustment and need for therapeutic drug monitoring.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022208
- 003
- CZ-PrNML
- 005
- 20250228133206.0
- 007
- ta
- 008
- 240104s2023 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/23362936.2023.34 $2 doi
- 035 __
- $a (PubMed)38069649
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Dvořáčková, Eliška $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 kv2015890922
- 245 10
- $a Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient / $c E. Dvořáčková, A. Zajacová, J. Havlín, E. Klapková, R. Lischke, O. Slanař, M. Šíma
- 520 9_
- $a Mucormycosis is a rare invasive fungal disease diagnosed in immunocompromised patients, including those with diabetes or iron overload, and in patients treated for hematological malignancies or after transplantation. Isavuconazole is a triazole antifungal effective against Mucorales with good tolerability, but with potential for relatively high interindividual variability in pharmacokinetics. This report demonstrates the case of a lung transplant recipient treated with isavuconasole that exhibits a very long elimination half-life of 159 hours, and discusses the practical implications of this finding for dosage adjustment and need for therapeutic drug monitoring.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a příjemce transplantátu $7 D066027
- 650 _2
- $a monitorování léčiv $7 D016903
- 650 12
- $a aspergilóza $x farmakoterapie $7 D001228
- 650 _2
- $a triazoly $x terapeutické užití $x farmakokinetika $7 D014230
- 650 12
- $a mukormykóza $x diagnóza $x farmakoterapie $7 D009091
- 650 _2
- $a plíce $7 D008168
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zajacová, Andrea $u Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $7 xx0280642
- 700 1_
- $a Havlín, Jan $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $7 xx0093656
- 700 1_
- $a Klapková, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $7 pna2011626059
- 700 1_
- $a Lischke, Robert, $u Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $d 1966- $7 xx0078729
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0058262
- 700 1_
- $a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. martin.sima@lf1.cuni.cz $7 xx0222901
- 773 0_
- $w MED00013414 $t Prague medical report $x 1214-6994 $g Roč. 124, č. 4 (2023), s. 444-448
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38069649 $y Pubmed
- 910 __
- $a ABA008 $b A 7 $c 1071 $y p $z 0
- 990 __
- $a 20240104 $b ABA008
- 991 __
- $a 20250228133158 $b ABA008
- 999 __
- $a ok $b bmc $g 2276371 $s 1208652
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 124 $c 4 $d 444-448 $e - $i 1214-6994 $m Prague medical report $n Prague Med Rep $x MED00013414
- GRA __
- $a 00064203 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $b NLK116 $a Pubmed-20240104
